Clinical trial
Randomized Phase II Study of Durvalumab and Tremelimumab Combination Versus Standard of Care Following First-line Platinum Based Chemotherapy in Two Cohorts of Patients With Non Squamous and Squamous Non-small-cell Lung Cancer (NSCLC)
NCT03319316 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II Study of Durvalumab and Tremelimumab Combination Versus Standard of Care Following First-line Platinum Based Chemotherapy in Two Cohorts of Patients With Non Squamous and Squamous Non-small-cell Lung Cancer (NSCLC)
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- November 1, 2018
- Completion date
- November 30, 2022
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
non-squamous non-small cell lung cancer, squamous non-small cell lung cancer